Windlas Biotech Ltd IPO Analysis
Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company is incorporated in 2001. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; CDMO Products and services, Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and Export.
Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
For FY 21, the company had total assets of Rs 2,961.23 million and a Revenue of Rs. 4,306.95 million. Total Assets and Revenue showed an increase from the past two financial years, which is a good sign.
The opening IPO date is Aug 4, 2021 till Aug 6, 2021 with the IPO price of Rs ₹448 to Rs 460 per equity share. The issue size of the IPO is supposed to be ₹401.54 Cr.
Windlas biotech ltd. is not highly recommended to buy for long term. The company might do well in future if they expand their operations abroad.
